Wells Fargo & Company Reiterates Overweight Rating for Omnicell (NASDAQ:OMCL)

Omnicell (NASDAQ:OMCL - Get Free Report)'s stock had its "overweight" rating reaffirmed by Wells Fargo & Company in a note issued to investors on Friday, MarketBeat Ratings reports. They presently have a $37.00 target price on the stock, up from their previous target price of $35.00. Wells Fargo & Company's price objective suggests a potential upside of 25.98% from the stock's current price.

Several other equities analysts also recently commented on OMCL. Benchmark cut their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. JPMorgan Chase & Co. cut their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, March 20th. Finally, Wall Street Zen upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, May 20th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Omnicell has a consensus rating of "Moderate Buy" and an average target price of $44.83.

Omnicell Trading Down 0.8%

NASDAQ OMCL traded down $0.24 during trading hours on Friday, hitting $29.37. 395,319 shares of the company were exchanged, compared to its average volume of 564,799. The stock has a market cap of $1.38 billion, a PE ratio of 108.78, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The stock has a 50-day moving average price of $30.70 and a 200 day moving average price of $38.41. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10. The company had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The firm's revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.03 EPS. Analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Hedge funds and other institutional investors have recently modified their holdings of the business. Smartleaf Asset Management LLC boosted its position in Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after acquiring an additional 273 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in Omnicell during the fourth quarter valued at about $37,000. Van ECK Associates Corp boosted its position in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after purchasing an additional 315 shares in the last quarter. Headlands Technologies LLC bought a new stake in Omnicell during the fourth quarter valued at about $53,000. Finally, First Horizon Advisors Inc. boosted its position in Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after purchasing an additional 355 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.